Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Vicente Carañana"'
Autor:
Alfonso Cortés, Elena López-Miranda, Adela Fernández-Ortega, Vicente Carañana, Sonia Servitja, Ander Urruticoechea, Laura Lema-Roso, Antonia Márquez, Alexandros Lazaris, Daniel Alcalá-López, Leonardo Mina, Petra Gener, Jose Rodríguez-Morató, Gabriele Antonarelli, Antonio Llombart-Cussac, José Pérez-García, Javier Cortés
Publikováno v:
Breast, Vol 78, Iss , Pp 103834- (2024)
Purpose: To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline BRCA1/2 mutations (gBRCA1/2mut). Methods: NOBROLA (NCT03367689) is a single-arm, open-label, multic
Externí odkaz:
https://doaj.org/article/b40824f923304c0d88d41f079397d8b6
Autor:
Antonio Llombart-Cussac, Ángel Guerrero-Zotano, Manuel Ruiz, Begoña Bermejo, Miguel Gil-Gil, Juan de la Haba, Emilio Alba, Vanesa Quiroga, Vicente Carañana, Ander Urruticoechea, Serafín Morales, Meritxell Bellet, Antonio Antón, José Manuel Pérez-García, María Fernández-Abad, Sonia Servitja, Pedro Sánchez-Rovira, Sofia Braga, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortes
Publikováno v:
Cancer Research. 82:P5-16
Background: Cyclin-dependent kinases 4 and 6 inhibitors in combination with endocrine therapy frequently lead to a complete cell-cycle arrest (CCCA) in luminal EBC. However, the rates of pathological complete response (pCR) or Residual Cancer Burden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2518c61e31e801617b7d107897e47761
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-12
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-12
Autor:
Juan Carlos Andreu-Ballester, José Manuel Pérez-García, Begoña Bermejo, Vicente Carañana, Vega Iranzo, Joaquín Gavilà, Ana Santaballa, María Carmen Gómez-Soler, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortes, Antonio Llombart-Cussac
Publikováno v:
Cancer Research. 82:P5-13
Background: The presence of stromal tumor-infiltrating lymphocytes (TILs) represents an independent prognostic factor in HER2-positive early-stage breast cancer (EBC) treated with trastuzumab/pertuzumab-containing regimens. Among distinct subsets of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1a26ca552d276980afc030f5447af1b
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-30
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-30
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J Gil Gil, Manuel Ruiz Borrego, Joaquín Gavilá, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez-De Dueñas, Vicente Carañana, Kepa Amillano, Leonardo Mina, Andrea Malfettone, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Scientia
Background Palbociclib has gained a central role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). Despite its manageable toxicity profile, venous thromboembo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94856ca3e331564bbf534f081808407
https://academic.oup.com/oncolo/article-pdf/28/1/23/48837357/oyac205.pdf
https://academic.oup.com/oncolo/article-pdf/28/1/23/48837357/oyac205.pdf
Autor:
Raúl Márquez Vázquez, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Jesus Soberino, Susana de la Cruz Sánchez, Peter Schmid, Aleix Prat, Miguel Angel Seguí-Palmer, María Gión Cortés, Andrea Malfettone, Vicente Carañana, Javier Cortes, Lourdes Calvo, Begoña Bermejo, Manuel Ruiz Borrego, Giuseppe Curigliano, Jose Luis Alonso, Jose Perez-Garcia, Elena López-Miranda
Publikováno v:
European Journal of Cancer. 148:382-394
Background Pembrolizumab has modest activity if used in patients with hormone-receptor–positive (HR+), HER2-negative, previously treated metastatic breast cancer (BC). Our study investigated whether there would be any clinical benefit in combining
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e77826c81ce42c3ca11452e8188ac513
https://doi.org/10.1016/j.ejca.2021.02.028
https://doi.org/10.1016/j.ejca.2021.02.028
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet Ezquerra, Florence Dalenc, Miguel Gil Gil, Manuel Ruiz Borrego, Joaquín Gavilá, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez De Dueñas, Vicente Carañana, Kepa Amillano, Andrea Malfettone, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Cancer Research. 83:PD13-10
Background The use of PPI among cancer patients (pts) is quite frequent. PAL is an oral, cyclin-dependent kinase 4 and 6 inhibitor recommended to be taken under fed conditions. PAL showed a reduced solubility when gastric pH is >4.5, a level commonly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5fa30dc0e39ab68e5fd07d0ee29827d
https://doi.org/10.1158/1538-7445.sabcs22-pd13-10
https://doi.org/10.1158/1538-7445.sabcs22-pd13-10
Autor:
Miguel Sampayo-Cordero, Manuel Ruiz Borrego, Andreas Schneeweiss, Elena Aguirre, Joaquín Gavilá, Florence Dalenc, Andrea Malfettone, Antonio Llombart-Cussac, Joan Albanell, Peter Schmid, Serena Di Cosimo, Miguel Gil, Meritxell Bellet, Pilar Zamora, Vicente Carañana, Joseph Gligorov, Javier Cortes, Duncan Wheatley, Jose Perez-Garcia, Kepa Amillano, Eduardo Martínez de Dueñas, Frederik Marmé
Publikováno v:
Cancer Research. 81:PS10-17
Background: P led to a meaningful improvement in clinical outcomes when used in combination with endocrine therapy for first- or later-line regimen in HR[+]/HER2[-] MBC. Grade 3-4 neutropenia was the most common adverse event (AE) in the P-containing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c5900e5e6ffa7982a9608ac18e6696e
https://doi.org/10.1158/1538-7445.sabcs20-ps10-17
https://doi.org/10.1158/1538-7445.sabcs20-ps10-17
Autor:
José Manuel Pérez-García, Antonio Llombart-Cussac, Esther Holgado, Giuseppe Curigliano, Elena López Miranda, José Luis Alonso-Romero, Begoña Bermejo, Lourdes Calvo, Vicente Carañana, Susana de la Cruz Sánchez, María Gión Cortés, Raúl Márquez Vázquez, Aleix Prat, Manuel Ruiz Borrego, Miguel Sampayo, Miguel Àngel Seguí, Jesus Soberino, Andrea Malfettone, Peter Schmid, Javier Cortés
Publikováno v:
Cancer Research. 80:P3-09
BACKGROUND: Studies of checkpoint inhibitor monotherapy have shown only modest activity in hormone receptor (HR)-positive (+)/human epidermal growth factor receptor 2 (HER2)-negative (-) metastatic breast cancer (MBC). However, pembrolizumab (P) adde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e349ff29c5e24cae828097f91532800
https://doi.org/10.1158/1538-7445.sabcs19-p3-09-03
https://doi.org/10.1158/1538-7445.sabcs19-p3-09-03
Autor:
Lorenzo Gerratana, Jean-Yves Pierga, James M Reuben, Andrew A Davis, Firas H Wehbe, Luc Dirix, Tanja Fehm, Franco Nolé, Rafael Gisbert-Criado, Dimitrios Mavroudis, Salvatore Grisanti, Jose A Garcia-Saenz, Justin Stebbing, Carlos Caldas, Paola Gazzaniga, Luis Manso, Rita Zamarchi, Marta Bonotto, Angela Fernandez de Lascoiti, Leticia De Mattos-Arruda, Michail Ignatiadis, Maria-Teresa Sandri, Daniele Generali, Carmine De Angelis, Sarah-Jane Dawson, Wolfgang Janni, Vicente Carañana, Sabine Riethdorf, Erich-Franz Solomayer, Fabio Puglisi, Mario Giuliano, Klaus Pantel, François-Clément Bidard, Massimo Cristofanilli
Publikováno v:
Scientia
Biomarker; Liquid biopsy; Machine learning Biomarcadores; Biopsia líquida; Aprendizaje automático Biomarcadors; Biòpsia líquida; Aprenentatge automàtic Despite the strong prognostic stratification of circulating tumor cells (CTCs) enumeration in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd28e762c51263f622c8e7d064b07334
http://hdl.handle.net/11368/3017431
http://hdl.handle.net/11368/3017431
Autor:
Salvatore Grisanti, Tanja Fehm, Daniele Generali, Jean-Yves Pierga, Dimitrios Mavroudis, Mario Giuliano, Leticia De Mattos-Arruda, Steven Van Laere, Lorenzo Gerratana, Francesca Consoli, Wolfgang Janni, Klaus Pantel, Luc Dirix, Stefan Michiels, Carlos Caldas, Annemie Rutten, Jorge S. Reis-Filho, Michail Ignatiadis, Dieter Peeters, Andrew M. Davis, Sarah-Jane Dawson, Jose Vidal-Martinez, Cristina Raimondi, Massimo Cristofanilli, Alfred Rademaker, Maria Teresa Sandri, Justin Stebbing, Rita Zamarchi, Franziska Meier-Stiegen, Elisabetta Munzone, Jonathan Krell, Vicente Carañana, Erich-Franz Solomayer, Laura Zorzino, Franco Nolè, Paola Gazzaniga, Eduardo Díaz-Rubio, Lauren Darrigues, Luc Cabel, Rafael Gisbert-Criado, Eleni Politaki, Sofia Agelaki, José A. García-Sáenz, Angela Fernandez de Lascoiti, Maria Rosa Cappelletti, Camillo Almici, Luis Manso, François-Clément Bidard, James M. Reuben
Publikováno v:
Critical reviews in oncology, hematology
Background: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ef4c527220afcd22fd71cd8f94b62a
https://hdl.handle.net/11368/2935442
https://hdl.handle.net/11368/2935442